Clinical Trials Directory

Trials / Completed

CompletedNCT02190786

Phase II Exploratory Clinical Study of KUX-1151

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
Sponsor
Kissei Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
20 Years – 64 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of multiple oral administration of KUX-1151 in patients with hyperuricemia including gout.

Conditions

Interventions

TypeNameDescription
DRUGKUX-1151

Timeline

Primary completion
2015-03-01
First posted
2014-07-15
Last updated
2015-10-19

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT02190786. Inclusion in this directory is not an endorsement.

Phase II Exploratory Clinical Study of KUX-1151 (NCT02190786) · Clinical Trials Directory